海德堡大学医院鼻咽癌调强放化疗结局与复发模式分析
该回顾性研究纳入2005—2019年48例接受调强放疗联合每周顺铂(40 mg/m²)的鼻咽癌患者,中位随访73个月,3/5/10年总生存率分别为98%/96%/67%,局部控制率2/3/5年均为92%/89%/89%,远处转移(13%)与局部复发(10%)为主要失败模式,局部复发多位于高剂量区。
要点
- 调强放疗联合每周顺铂治疗鼻咽癌获得优异生存与局部区域控制,毒性可接受。
- 远处转移为13%,是主要失败模式之一,提示需更有效的全身治疗。
- 多数局部复发位于高剂量区,提示存在治疗优化的潜在空间。
核心结论
- 调强放疗联合每周顺铂在鼻咽癌中产生优异的生存和局部区域控制,毒性可接受。
- 远处转移是主要失败模式之一,凸显需要更有效的全身治疗。
- 多数局部复发发生于高剂量区,提示存在治疗优化的潜在机会。
研究设计与样本
- 回顾性分析2005—2019年海德堡大学医院48例接受调强放疗联合每周顺铂(40 mg/m²)的鼻咽癌患者。
- PTV中位总剂量57.6 Gy(1.8 Gy/次),原发肿瘤及淋巴结转移灶同步整合加量至70.4 Gy。
- 随访影像与计划CT可变形配准,勾画复发大体肿瘤体积并映射至计划CT,按质心系统将复发分为A至E五型。
主要发现
- 中位随访73个月(范围24—156),9例(19%)死亡。
- 3年、5年、10年总生存率分别为98%、96%、67%。
- 局部控制率2年、3年、5年分别为92%、89%、89%;区域控制分别为96%、94%、94%;远处控制分别为92%、89%、89%。
- 无≥4级毒性;3级急性毒性23例(48%),最常见为吞咽困难,几乎所有均在90天内缓解。
- 治疗失败中远处转移(13%)和局部复发(10%)最常见;分析的8例局部和/或区域复发中,2例为A型(中央高剂量)、3例为B型(边缘)、2例为C型(中央中/低剂量)、1例为E型(野外)。
关键数值与推荐
- 复发分型标准:基于质心系统分为A型(中央高剂量)、B型(周边高剂量)、C型(中央中/低剂量)、D型(周边中/低剂量)、E型(野外剂量)。
- 3级急性毒性发生于23例(48%),最常见为吞咽困难,几乎所有均在90天内缓解。
临床怎么用
- 调强放疗联合每周顺铂可作为鼻咽癌的有效治疗方案,生存和局部区域控制优异且毒性可接受。
- 远处转移为主要失败模式之一,临床应考虑加强全身治疗策略。
- 多数局部复发位于高剂量区,提示可探索治疗优化以进一步改善局部控制。
局限性
- 回顾性研究设计,样本量48例,结果需前瞻性研究验证。
- 局部和/或区域复发仅8例可用于复发模式分析,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To evaluate treatment outcomes, toxicity, and recurrence patterns by dose level in nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT) and weekly cisplatin. METHODS: We retrospectively analyzed 48 NPC patients treated between 2005 and 2019 with IMRT and weekly cisplatin (40 mg/m²). The planning target volume (PTV) received a median total dose of 57.6 Gy (1.8 Gy/fraction) with a simultaneous integrated boost to the primary tumor and nodal metastases up to 70.4 Gy. To assess recurrence patterns, follow-up imaging was deformably co-registered with planning CTs (pCT), and recurrent gross tumor volumes (rGTVs) were delineated and mapped to pCTs. Recurrences were categorized using a centroid-based system into five types: A (central high-dose), B (peripheral high-dose), C (central intermediate-/low-dose), D (peripheral intermediate-/low-dose), and E (extraneous dose). RESULTS: With a median follow-up of 73 months (range 24-156), 9 patients (19%) had died. The 3-, 5-, and 10-year overall survival rates were 98%, 96%, and 67%, respectively. Local control rates (LCR) at 2, 3, and 5 years were 92%, 89%, and 89%; regional control was 96%, 94%, and 94%; and distant control was 92%, 89%, and 89%. Treatment was well tolerated, with no grade ≥ 4 toxicities. Grade 3 acute toxicities occurred in 23 patients (48%), most commonly dysphagia, with nearly all resolving within 90 days. Among treatment failures, distant metastases (13%) and local relapses (10%) were most frequent. Of 8 local and/or regional recurrences analyzed, 2 were type A (central high-dose), 3 type B ("marginal"), 2 type C (central intermediate-/low-dose), and 1 type E ("out-of-field"). CONCLUSION: IMRT with weekly cisplatin yields excellent survival and locoregional control with acceptable toxicity in NPC. Distant metastasis as one of the predominant failure patterns highlights the need for more effective systemic therapies. Most local recurrences arose within high-dose areas, suggesting a potential opportunity for treatment optimization.
引用
- Bauer L, Regnery S, Deng MY, et al. Outcomes and recurrence pattern analysis of intensity modulated chemoradiotherapy in nasopharyngeal cancer: a retrospective study from Heidelberg University Hospital. Radiat Oncol. 2025. PMID: 41361781. doi:10.1186/s13014-025-02769-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。